Laboratory Assessment of Coagulation Factor XIII

Abstract

Laboratory diagnosis of congenital and acquired deficiencies of coagulation factor XIII (FXIII) can be challenging. Determination of FXIII function requires specific and sensitive assays which are not always available. This brief review article summarizes currently used FXIII assay methods, their principles and difficulties, and discusses the recommended diagnostic workup in case of a suspected FXIII deficiency. The article also briefly touches on experimental methods used in FXIII research.

Keywords

coagulation factor XIII - factor XIII assay - FXIII deficiency

Publikationsverlauf

Eingereicht: 15. April 2020

Angenommen: 18. Mai 2020

Artikel online veröffentlicht:
31. August 2020

• References

• 1 Muszbek L, Bereczky Z, Bagoly Z, Komáromi I, Katona É. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011; 91 (03) 931-972
• 2 Schroeder V, Kohler HP. Factor XIII: structure and function. SeminThrombHemost 2016; 42 (04) 422-428
• 3 Schroeder V, Kohler HP. Factor XIII deficiency: an update. SeminThrombHemost 2013; 39 (06) 632-641
• 4 Jennings I, Kitchen S, Woods TAL, Preston FE. UK NEQAS. Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study. J ThrombHaemost 2003; 1 (12) 2603-2608
• 5 Jennings I, Kitchen S, Menegatti M. et al. Detection of factor XIII deficiency: data from multicentre exercises amongst UK NEQAS and PRO-RBDD project laboratories. Int J Lab Hematol 2017; 39 (04) 350-358
• 6 Muszbek L, Polgár J, Fésüs L. Kinetic determination of blood coagulation factor XIII in plasma. Clin Chem 1985; 31 (01) 35-40
• 7 Kárpáti L, Penke B, Katona E, Balogh I, Vámosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem 2000; 46 (12) 1946-1955
• 8 Ajzner E, Muszbek L. Kinetic spectrophotometric factor XIII activity assays: the subtraction of plasma blank is not omissible [corrected]. J ThrombHaemost 2004; 2: 2075-2077
• 9 Cini M, Legnani C, Frascaro M. et al. Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies. Clin Chem Lab Med 2016; 54 (05) 805-809
• 10 Raut S, Merton RE, Rigsby P. et al; ISTH/SSC Factor XIII Subcommittee and the Factor XIII Standardization Working Party. A collaborative study to establish the 1st International Standard for factor XIII plasma. J ThrombHaemost 2007; 5 (09) 1923-1929
• 11 Li B, Billur R, Maurer MC. et al. Proline 36 of the factor XIII activation peptide plays a crucial role in substrate recognition and zymogen activation. ThrombHaemost 2018; 118 (12) 2037-2045
• 12 Muszbek L, Katona É. Diagnosis and management of congenital and acquired FXIII deficiencies. SeminThrombHemost 2016; 42 (04) 429-439
• 13 Ichinose A. Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: a summary of 93 patients. Blood Rev 2017; 31 (01) 37-45
• 14 Bridey F, Négrier C, Duval C, Ariëns R, de Moerloose P, Casini A. Impaired factor XIII activation in patients with congenital afibrinogenemia. Haematologica 2019; 104 (03) e111-e113
• 15 Hitomi K, Kitamura M, Alea MP, Ceylan I, Thomas V, El Alaoui S. A specific colorimetric assay for measuring transglutaminase 1 and factor XIII activities. Anal Biochem 2009; 394 (02) 281-283
• 16 Kohler HP, Ariëns RA, Whitaker P, Grant PJ. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. ThrombHaemost 1998; 80 (04) 704
• 17 Oertel K, Hunfeld A, Specker E. et al. A highly sensitive fluorometric assay for determination of human coagulation factor XIII in plasma. Anal Biochem 2007; 367 (02) 152-158
• 18 Dodt J, Volkers P, Seitz R. Factor XIIIa generation assay: a tool for studying factor XIII function in plasma. Anal Biochem 2013; 439 (02) 145-151
• 19 Leitner M, Büchold C, Pasternack R, Binder NB. Feasibility of an automated coagulation factor XIIIa test using its isopeptidase activity. Anal Biochem 2020; 600: 113757
• 20 Kohler HP, Ichinose A, Seitz R, Ariëns RAS, Muszbek L. Factor XIII And Fibrinogen SSC Subcommittee Of The ISTH. Diagnosis and classification of factor XIII deficiencies. J ThrombHaemost 2011; 9 (07) 1404-1406
• 21 Muszbek L, Pénzes K, Katona É. Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences. J ThrombHaemost 2018; 16 (05) 822-832
• 22 Ichinose A, Kohler HP, Philippou H. Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Recommendation for ISTH/SSC Criterion 2015 for autoimmune acquired factor XIII/13 deficiency. ThrombHaemost 2016; 116 (04) 772-774
• 23 Dorgalaleh A, Farshi Y, Alizadeh SH. et al. Challenges in implementation of ISTH diagnostic algorithm for diagnosis and classification of factor XIII deficiency in Iran. J ThrombHaemost 2015; 13 (09) 1735-1736
• 24 Ortner E, Schroeder V, Walser R, Zerbe O, Kohler HP. Sensitive and selective detection of free FXIII activation peptide: a potential marker of acute thrombotic events. Blood 2010; 115 (24) 5089-5096
• 25 Allan P, Uitte de Willige S, Abou-Saleh RH, Connell SD, Ariëns RAS. Evidence that fibrinogen γ′ directly interferes with protofibril growth: implications for fibrin structure and clot stiffness. J ThrombHaemost 2012; 10 (06) 1072-1080
• 26 Schroeder V, Kohler HP. Thrombelastographic studies on factor XIII. ThrombHaemost 2010; 104 (06) 1277-1279
• 27 Martinuzzo M, Barrera L, Altuna D. et al. Effects of factor XIII deficiency on thromboelastography. Thromboelastography with calcium and streptokinase addition is more sensitive than solubility tests. Mediterr J Hematol Infect Dis 2016; 8 (01) e2016037
• 28 Duval C, Ali M, Chaudhry WW, Ridger VC, Ariëns RA, Philippou H. Factor XIII A-subunit V34L variant affects thrombus cross-linking in a murine model of thrombosis. ArteriosclerThrombVasc Biol 2016; 36 (02) 308-316
• 29 Tsai M, Kita A, Leach J. et al. In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest 2012; 122 (01) 408-418
• 30 Jenny L, Dobó J, Gál P, Pál G, Lam WA, Schroeder V. MASP-1 of the complement system enhances clot formation in a microvascular whole blood flow model. PLoS One 2018; 13 (01) e0191292